CD274 and breast cancer: Moreover, olaparib combined with the PD-1/PD-L1 inhibitors, such as pembrolizumab (NCT04191135), atezolizumab (NCT02849496), and durvalumab (NCT03167619), is currently being tested for the treatment of gBRCA1/2-mutated BC.